Abnormalities of the mixed-lineage leukemia (MLL) gene on chromosome band 11q23 can be detected in de novo acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as well as in therapy-related AML, particularly after treatment with DNA topoisomerase II inhibitors. 1 To date, more than 50 different translocations involving the MLL gene have been described, and so far up to 37 different partner genes have been cloned. The t(4;11)(q21;q23) results in the MLL-AF4 fusion gene and is the most frequent MLL translocation in ALL, but is rare in AML. The t(11;19)(q23;p13.3) generates the MLL-ENL fusion gene and is observed with equal frequency in AML and ALL, whereas t(9;11)(p21-22;q23), resulting in the MLL-AF9 fusion gene, is the most common MLL abnormality in AML.
In infant ALL, any MLL rearrangement is associated with poor prognosis, whereas in older ALL patients, the presence of MLL-AF4 and MLL-AF9 fusion genes is associated with a worse outcome compared to other MLL rearrangements. 2 For example, ALL patients with MLL-ENL fusion gene transcripts tend to have a better prognosis than patients harboring MLL-AF4. 2 In AML, MLL-AF9 has generally been associated with a more favorable outcome. Therefore, detection and identification of the different types of MLL rearrangements is of clinical importance.
Various methods are available for the detection of MLL translocations, including cytogenetic analysis and molecular techniques like Southern blot analysis, (split-signal) fluorescence in situ hybridization (FISH) and reverse-transcriptase polymerase chain reaction (RT-PCR). Southern blot and split-signal FISH analysis of the MLL gene do not provide information on the involved partner gene, which can be identified by RT-PCR analysis for the most frequently occurring MLL translocations. Multiplex RT-PCR has previously been described for the simultaneous detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts. 3 However, such classical end-stage RT-PCR is time consuming and post-PCR handling increases the risk of PCR product contamination. These limitations can be overcome by real-time quantitative (RQ-)PCR, but so far the reported RQ-PCR approaches focused on detection of a single MLL translocation only. 4, 5 In addition, with the classical RT-PCR, only qualitative data can be obtained, but a recent study indicates that quantification by RQ-PCR of the fusion gene transcript levels at diagnosis may be of prognostic relevance. 6 Therefore, our aim was to develop a multiplex RQ-PCR strategy for the simultaneous detection of all previously described variants of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts. Such multiplex assay is preferred, given the low frequency of MLL rearrangements in ALL and AML (generally less than 5-10% of patients). To this end, we evaluated the usage of hydrolysis probes using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, USA) and hybridization probes in the LightCycler (Roche Diagnostics, Basel, Switzerland).
Primers and hydrolysis probes were designed using PrimerExpress software (Applied Biosystems) and OLIGO 6.0 according to the manufacturer's guidelines. Hybridization probes were designed by TIB MolBiol (Berlin, Germany). Primers and probes were designed in the MLL, AF4, AF9 or ENL genes in such a way that all previously reported breakpoints could be detected (Figure 1) . 3, 7, 8 RNA of cell lines and infant ALL patients was isolated using a GeneElute Mammalian Total RNA isolation kit (Sigma, St Louis, USA) according to the manufacturer's instructions. A cDNA reaction was performed using the previously described BIOMED-1 protocol. 9 The quality and quantity of cDNA samples was evaluated using an ABL RQ-PCR as previously described. 10 All patient samples, negative and positive controls were analyzed in duplicate. Primers and probes were tested using cell lines positive for MLL-AF4 (RS4;11, MV4-11 and ALL-PO for the e10-e4, e9-e5 and e11-e5 variants, respectively) or MLL-AF9 (THP-1 and MonoMac6 for the e9-e5 and e11-e5 variants, respectively) or using an MLL-ENL-positive patient sample (ENLC3 with the e10-e2 variant).
First, fusion gene-specific multiplex RQ-PCRs containing two forward MLL primers, two MLL probes and either two AF4, three AF9 or two ENL reverse primers were developed for the TaqMan and for the LightCycler. All three multiplex RQ-PCRs efficiently detected corresponding fusion transcript variants of MLL-AF4, MLL-AF9 and MLL-ENL in control samples. Subsequently, full multiplex RQ-PCRs containing two forward MLL primers, two MLL probes and two AF4, three AF9 and two ENL reverse primers were developed for the TaqMan and for the LightCycler to simultaneously detect MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts. Both RQ-PCRs resulted in robust and efficient detection of fusion gene transcripts in control samples (delta Rn41, Ct singleplex ¼ Ct multiplex (range 22-26 cycles).
The multiplex RQ-PCR in both TaqMan and LightCycler was validated on 21 infant ALL samples and 40 adult AML cases. Six infant ALL cases had an MLL-AF4 fusion gene transcript, three infants had MLL-AF9, six infants had MLL-ENL, two infants had other MLL fusion partner genes and four infants did not have an MLL translocation as determined by 'classical' RT-PCR analysis and split-signal FISH. One AML was t(4;11) positive, seven cases contained t(9;11) and three cases had t(11;19), as determined by cytogenetic analysis. Validation was conducted blindly, without previous knowledge of the presence of a translocation in the samples. Using the full multiplex RQ-PCR in both RQ-PCR approaches, all 15 positive infant ALL samples and nine out of 11 positive adult AML patients were recognized (see Figure 2a for TaqMan results). All positive patient samples were further analyzed using the fusion gene-specific multiplex RQ-PCR, resulting in correct identification of the MLL fusion gene transcript. In two AML patient samples with cytogenetically identified t(11;19), no MLL-ENL fusion gene transcript could be detected by RQ-PCR. DNA sequencing of the MLL breakpoint region of one of these patients revealed a t(11;19)(q23;p13.1) resulting in MLL-ELL fusion gene transcript. No DNA for sequencing the MLL breakpoint region was available of the other patient. Although false negativity formally cannot be excluded, this patient most likely contains t(11;19)(q23;p13.1) resulting in MLL-ELL or t(11;19)(q23;p13) generating MLL-EEN fusion gene transcript, or this patient might bear a breakpoint in the ENL gene not yet described in the literature, which could not be detected by the used primer pairs. No false-positive results were obtained using multiplex RQ-PCR in either TaqMan or LightCycler.
In conclusion, we designed a multiplex RQ-PCR for both TaqMan and LightCycler for the simultaneous detection of most fusion transcript variants of MLL-AF4, MLL-AF9 and MLL-ENL in acute leukemia patients. This assay can be used for easy and efficient detection of the most frequent MLL rearrangements in ALL and AML. In case of positivity, the fusion gene-specific multiplex RQ-PCR can be used for the identification of the involved fusion gene. The designed RQ-PCR primer-probe sets can also be used for detection of minimal residual disease during and after therapy. 
